Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD TSXV Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2024-12-21 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 certification by the CFO attesting to the accuracy of interim financial filings under Canadian Regulation 52-109. It is not the interim report itself, earnings release, MD&A, or any investor presentation, but rather a regulatory certification form. This does not fit any specific filing category except the general fallback “Regulatory Filings” (RNS).
2024-12-21 English
52-109FV2 - Certification of interim filings - CEO (F).pdf
Regulatory Filings Classification · 1% confidence The document is a short (≈3,600 characters) CEO attestation under Canadian NI 52-109 relating to interim financial and management reports for the quarter ended 31 October 2024. It does not contain the full interim financial statements or MD&A themselves, nor is it announcing dividends, board changes, or a capital action. It is a regulatory‐required certification attestation, fitting none of the specific categories other than the general fallback for miscellaneous filings. As such, it should be classified as a Regulatory Filing (RNS).
2024-12-21 French
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 “Venture Issuer Basic Certificate” certifying that the interim financial report and interim MD&A for the period ended October 31, 2024 have been reviewed and fairly present the issuer’s financial condition. It is not the interim report itself but a short certification filing under Canadian securities regulation. It does not provide financial results or discussion but serves as a regulatory compliance certificate. Therefore, it best fits the fallback category for miscellaneous regulatory filings (RNS).
2024-12-21 English
Interim MD&A - French.pdf
Management Reports Classification · 1% confidence The document is titled “Rapport de gestion – pour le trimestre terminé le 31 octobre 2024,” which in Canadian/IFRS filings corresponds to a Management Discussion & Analysis covering the quarterly period. It provides management’s detailed narrative on financial results, business trends, and outlook, rather than just key headline figures or the full audited financial statements. This aligns directly with the “Management Reports (MDA)” category.
2024-12-21 French
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is clearly titled “Management’s Discussion and Analysis – For the quarter ended October 31, 2024” and contains narrative analysis of financial results, operating highlights, R&D updates, and forward-looking statements. It is not a short announcement nor a full annual or quarterly financial report, but rather the MD&A section, matching the definition of a Management Report (MDA).
2024-12-21 English
Interim financial statements/report – French.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'États financiers consolidés intermédiaires' (Interim Consolidated Financial Statements) for the three-month periods ended October 31, 2024 and 2023. It contains comprehensive financial statements (Statement of Financial Position, Statement of Net Income and Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed explanatory notes. It is not an announcement or a summary, but the full interim financial report itself. Therefore, it is classified as an Interim/Quarterly Report. Q1 2025
2024-12-21 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.